Compare · BGLC vs CI
BGLC vs CI
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.96B, about 22044.6x BGLC ($3.6M).
- CI has been more active in the news (5 items in the past 4 weeks vs 2 for BGLC).
- CI has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- The Cigna Group
- Price
- -
- -
- Market cap
- $3.6M
- $78.96B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 5
- Recent ratings
- 0
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest BGLC
- SEC Form 8-K filed by BioNexus Gene Lab Corp
- RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
- Chief Executive Officer Tan Lee Su-Leng was granted 338,709 shares (SEC Form 4)
- Director Yap Chee Keong was granted 32,258 shares (SEC Form 4)
- Director Bin Abdul Hamid Muhammad Azrul was granted 32,258 shares (SEC Form 4)
- Chief Financial Officer Chong Set Fui was granted 96,774 shares (SEC Form 4)
- Director Low Jook Yuen was granted 16,129 shares, increasing direct ownership by 1,279% to 17,390 units (SEC Form 4)
- SEC Form 10-Q filed by BioNexus Gene Lab Corp
- New insider Fidelion Diagnostics Pte. Ltd. claimed ownership of 392,329 shares (SEC Form 3)
- New insider Tan Lee Su-Leng claimed no ownership of stock in the company (SEC Form 3)
Latest CI
- SEC Form 8-K filed by The Cigna Group
- The Cigna Group's Third Quarter 2026 Earnings Release Details
- Cigna Healthcare Introduces Health Sense To Connect Guidance, Benefits and Clinical Support Around Each Person, Improving Affordability and Outcomes
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- The Cigna Group Hosts 2026 Investor Day; Introduces "Lead to One" to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities
- Is Volunteering Good for Your Health? New Research From The Cigna Group Finds a Strong Connection
- Evercore ISI initiated coverage on The Cigna Group with a new price target
- The Cigna Group to Host Investor Day on September 30
- Officer Neville Everett sold $175,259 worth of shares (617 units at $284.05) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 5,053 units (SEC Form 4)
- Officer Evanko Brian C was granted 3,113 shares, increasing direct ownership by 8% to 41,030 units (SEC Form 4)